A+KIDS is unique from traditional prior-authorization policies in that it does not restrict access to specific antipsychotic treatments or clinical conditions. The only criterion followed in the authorization process is prescriber entry of clinical and safety information. During initial prescribing, providers are asked to enter patient characteristics, the prescribed medication, the symptom targeted, and the primary diagnosis for treatment. Safety monitoring data collected by A+KIDS for patients who have received six months of treatment or longer include weight and height, potential daytime sedation, blood glucose monitoring, and lipid screening. Neurological side effects, including tremors, muscle stiffness, restlessness, and involuntary muscle movements, are also documented. Clinical and safety information is requested to be updated every six months for patients using antipsychotics for off-label conditions and annually for patients with U.S. Food and Drug Administration–approved indications. Prescribers maintain their ability to use clinical judgment as to whether a monitoring test is necessary and may use the tool to monitor patient progress. They have the option of stating that the monitoring is not clinically indicated and allowing a patient’s family or guardian the choice to deny monitoring.